Captrust Financial Advisors Gritstone Bio, Inc. Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 38,659 shares of GRTS stock, worth $773. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,659
Previous 38,606
0.14%
Holding current value
$773
Previous $99,000
76.77%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding GRTS
# of Institutions
75Shares Held
37.5MCall Options Held
1.46MPut Options Held
168K-
Redmile Group, LLC San Francisco, CA5.11MShares$102,1540.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.64MShares$92,8780.0% of portfolio
-
Morgan Stanley New York, NY4.45MShares$89,0800.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA3.56MShares$71,2235.41% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL3.46MShares$69,2290.01% of portfolio
About Gritstone bio, Inc.
- Ticker GRTS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,006,896
- Market Cap $1.46M
- Description
- Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...